1-20 of 105
Guillermo Montalban-Bravo, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinicopathologic Correlates and Natural History of Atypical Chronic Myeloid Leukemia

Guillermo Montalban Bravo, MD, Rashmi Kanagal-Shamanna, MD, Koji Sasaki, MD, Lucia Masarova, MD, Kiran Naqvi, MD MPH, Elias Jabbour, MD, Courtney D. DiNardo, MD MSCE, Koichi Takahashi, MD PhD, Marina Konopleva, MD PhD, Naveen Pemmaraju, MD, Nicholas J. Short, MD, Ghayas C. Issa, MD, Tapan M. Kadia, MD, Farhad Ravandi, MBBS, Naval Daver, MD, Gautam Borthakur, MD, Zeev E. Estrov, MD, Joseph D. Khoury, MD, Sanam Loghavi, MD, Sherry A. Pierce, BSN, BA, Carlos E. Bueso-Ramos, MD PhD, Keyur Patel, MD PhD, Srdan Verstovsek, MD PhD, Hagop M. Kantarjian, MD, Prithviraj Bose, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 54–56.
https://doi.org/10.1182/blood-2020-137176
Published: 2020
Journal Articles

Activity of Venetoclax-Based Therapy in CMML and CMML with Blast Transformation

Danielle Hammond, MD, Courtney D. DiNardo, MD MSCE, Marina Konopleva, MD PhD, Gautam Borthakur, MD, Jorge M. Ramos Perez, MD, Veronica A Guerra, MD, Rashmi Kanagal-Shamanna, MD, Shilpa Paul, PharmD, Kiran Naqvi, MD MPH, Koji Sasaki, MD, Elias Jabbour, MD, Naveen Pemmaraju, MD, Tapan M. Kadia, MD, Farhad Ravandi, MBBS, Naval Daver, MD, Zeev E. Estrov, MD, Sherry A. Pierce, BSN, BA, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Guillermo Montalban-Bravo, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 36–37.
https://doi.org/10.1182/blood-2020-136385
Published: 2020
Journal Articles

Long-Term Outcome of Low-Dose Hypomethylating Agents in Lower-Risk Myelodysplastic Syndromes: A Randomized Phase 2 Study

Koji Sasaki, MD, Elias Jabbour, MD, Guillermo Montalban Bravo, MD, Nicholas J. Short, MD, Rashmi Kanagal-Shamanna, MD, Tapan M. Kadia, MD, Gautam Borthakur, MD, Naveen Pemmaraju, MD, Jorge E. Cortes, MD, Farhad Ravandi, MBBS, Yesid Alvarado, MD, Kelly S. Chien, MD, Hui Yang, MD PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 46–47.
https://doi.org/10.1182/blood-2020-139817
Published: 2020
Journal Articles

SF3B1 -Mutant Myelodysplastic Syndrome with Ringed Sideroblasts (MDS-RS) at the Single-Cell Level

Rashmi Kanagal-Shamanna, MD, Vera Adema, PhD, Feiyang Ma, Bs, Andrea Santoni, PhD, Hui Yang, MD PhD, Irene Ganan-Gomez, PhD, Natthakan Thongon, PhD, Guillermo Montalban-Bravo, MD, Matteo Pellegrini, PhD, Carlos E. Bueso-Ramos, MD PhD, Guillermo Garcia-Manero, MD, Simona Colla, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 50–51.
https://doi.org/10.1182/blood-2020-141928
Published: 2020
Journal Articles

Prognostic Value of Measurable Residual Disease after Venetoclax and Decitabine in Acute Myeloid Leukemia

Abhishek Maiti, MBBS, Courtney D. DiNardo, MD MSCE, Sa A Wang, MD, Jeffrey L. Jorgensen, MD PhD, Tapan M. Kadia, MD, Naval Daver, MD, Nicholas J. Short, MD, Musa Yilmaz, MD, Naveen Pemmaraju, MD, Gautam Borthakur, MD, Prithviraj Bose, MD, Ghayas C. Issa, MD, Alessandra Ferrajoli, MD, Elias Jabbour, MD, Nitin Jain, MD, Guillermo Garcia-Manero, MD, Maro Ohanian, DO, Koichi Takahashi, MD PhD, Guillermo Montalban-Bravo, MD, Lucia Masarova, MD, Jan A. Burger, MD PhD, Philip A. Thompson, MB, MS, Srdan Verstovsek, MD PhD, Koji Sasaki, MD, Michael Andreeff, MD PhD, Caitlin R. Rausch, PharmD, Kathryn Montalbano, Sherry A. Pierce, BSN, BA, Hagop M. Kantarjian, MD, Marina Konopleva, MD PhD, Farhad Ravandi, MBBS
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–25.
https://doi.org/10.1182/blood-2020-138773
Published: 2020
Journal Articles

Outcomes with Sequential FLT3-Inhibitor (FLT3i) Based Therapies in Patients (pts) with FLT3 -Mutated Acute Myeloid Leukemia (AML) Exposed to Prior FLT3i Based Therapies

Musa Yilmaz, MD, Mansour Alfayez, Tapan M. Kadia, MD, Courtney D. DiNardo, MD MSCE, Gautam Borthakur, MD, Sanam Loghavi, MD, Marina Konopleva, MD PhD, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD PhD, Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Naveen Pemmaraju, MD, Sherry A. Pierce, BSN, BA, Ghayas C. Issa, MD, Nicholas J. Short, MD, Guillermo Montalban Bravo, MD, Koichi Takahashi, MD PhD, Rita Assi, MD, Ahmad S Alotaibi, Michael Andreeff, MD PhD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Naval Daver, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–24.
https://doi.org/10.1182/blood-2020-139476
Published: 2020
Journal Articles

Response Patterns and MRD By Flow Cytometry and NGS in Patients with Mutant-IDH Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents

Danielle Hammond, MD, Sanam Loghavi, MD, Marina Konopleva, MD PhD, Tapan M. Kadia, MD, Naval Daver, MD, Maro Ohanian, DO, Ghayas C. Issa, MD, Yesid Alvarado, MD, Guillermo Montalban-Bravo, MD, Guillermo Garcia-Manero, MD, Gautam Borthakur, MD, Farhad Ravandi, MBBS, Koichi Takahashi, MD PhD, Hagop M. Kantarjian, MD, Courtney D. DiNardo, MD MSCE
Journal: Blood
Blood (2020) 136 (Supplement 1): 35–36.
https://doi.org/10.1182/blood-2020-141380
Published: 2020
Journal Articles

Evolutionary Action Score Identifies a Subset of TP53 Mutated Myelodysplastic Syndrome with Favorable Prognosis

Rashmi Kanagal-Shamanna, MD, Guillermo Montalban Bravo, MD, Panagiotis Katsonis, Koji Sasaki, MD, Caleb Class, PhD, Christopher B. Benton, MD, Elias Jabbour, MD, Kelly S. Chien, MD, Rajyalakshmi Luthra, PhD, Carlos E. Bueso-Ramos, MD PhD, Tapan M. Kadia, MD, Michael Andreeff, MD PhD, Nicholas J. Short, MD, Naval Daver, MD, Mark Routbort, MD PhD, Joseph D. Khoury, MD, Keyur Patel, MD PhD, Irene Ganan-Gomez, PhD, Yue Wei, PhD, Gautam Borthakur, MD, Farhad Ravandi, MBBS, Kim-Anh Do, PhD, Kelly A. Soltysiak, PhD, Olivier Lichtarge, L. Jeffrey Medeiros, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 4–5.
https://doi.org/10.1182/blood-2020-141411
Published: 2020
Journal Articles

A Phase II Study of Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS)

Kiyomi Morita, MDPhD, Hagop M. Kantarjian, MD, Guillermo Montalban Bravo, MD, Koji Sasaki, MD, Naval Daver, MD, Elias Jabbour, MD, Yesid Alvarado, MD, Kelly S. Chien, MD, Courtney D. DiNardo, MD MSCE, Farhad Ravandi, MBBS, Gautam Borthakur, MD, Prithviraj Bose, MD, Naveen Pemmaraju, MD, Kiran Naqvi, MD MPH, Jorge E. Cortes, MD, Tapan M. Kadia, MD, Marina Konopleva, MD PhD, Caitlin R. Rausch, PharmD, Yvonne Gasior, RN, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 7–9.
https://doi.org/10.1182/blood-2020-142003
Published: 2020
Journal Articles

Phase II Study of Venetoclax Added to Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Tapan M. Kadia, MD, Gautam Borthakur, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Courtney D. DiNardo, MD MSCE, Koji Sasaki, MD, Ghayas C. Issa, MD, Maro Ohanian, DO, Guillermo Montalban Bravo, MD, Nicholas J. Short, MD, Nitin Jain, MD, Alessandra Ferrajoli, MD, Kapil N. Bhalla, MD, Elias Jabbour, MD, Rashmi Kanagal-Shamanna, MD, Koichi Takahashi, MD PhD, Rashmi Malla, RN, BSN, Kelly Marek, Mark Brandt, BS, Uday R. Popat, MD, Michael Andreeff, MD PhD, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD, Marina Konopleva, MD PhD, Farhad Ravandi, MBBS, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 17–19.
https://doi.org/10.1182/blood-2020-142092
Published: 2020
Journal Articles

Prognostic and Therapeutic Implications of Mutant TP53 Variant Allelic Frequency in Adults with Newly Diagnosed TP53 -Mutated Acute Myeloid Leukemia

Nicholas J. Short, MD, Guillermo Montalban-Bravo, MD, Hyunsoo Hwang, Jing Ning, PhD, Miguel Franquiz, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD PhD, Courtney D. Dinardo, MDMSc, Farhad Ravandi, MBBS, Guillermo Garcia-Manero, MD, Koichi Takahashi, MD PhD, Marina Konopleva, MD PhD, Naval Daver, MD, Elias Jabbour, MD, Musa Yilmaz, MD, Ghayas C. Issa, MD, Michael Andreeff, MD PhD, Tapan M. Kadia, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 33–34.
https://doi.org/10.1182/blood-2020-134312
Published: 2020
Journal Articles

Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML

Curtis Lachowiez, MD, Marina Konopleva, MD PhD, Tapan M. Kadia, MD, Naval Daver, MD, Sanam Loghavi, MD, Sa A Wang, MD, Maria Adeoti, R.N., Sherry A. Pierce, BSN, BA, Koichi Takahashi, MD PhD, Nicholas J. Short, MD, Koji Sasaki, MD, Gautam Borthakur, MD, Ghayas C. Issa, MD, William G. Wierda, MD PhD, Naveen Pemmaraju, MD, Guillermo Montalban Bravo, MD, Alessandra Ferrajoli, MD, Nitin Jain, MD, Lucia Masarova, MD, Musa Yilmaz, MD, Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Steven M. Kornblau, MD, Farhad Ravandi, MBBS, Hagop M. Kantarjian, MD, Courtney D. Dinardo, MDMSc
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–20.
https://doi.org/10.1182/blood-2020-134300
Published: 2020
Journal Articles

Quizartinib with Decitabine +/- Venetoclax Is Highly Active in Patients (Pts) with FLT3 -ITD Mutated (mut) Acute Myeloid Leukemia (AML): Clinical Report and Signaling Cytof Profiling from a Phase IB/II Trial

Musa Yilmaz, MD, Hagop M. Kantarjian, MD, Muharrem Muftuoglu, Tapan M. Kadia, MD, Marina Konopleva, MD PhD, Gautam Borthakur, MD, Courtney D. DiNardo, MD MSCE, Naveen Pemmaraju, MD, Nicholas J. Short, MD, Yesid Alvarado, MD, Guillermo Montalban Bravo, MD, Carissa Jurisprudencia, Allison M. Pike, RN, Maro Ohanian, DO, Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Vivian Ruvolo, MS, Farhad Ravandi, MBBS, Michael Andreeff, MD PhD, Naval Daver, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 19–20.
https://doi.org/10.1182/blood-2020-142687
Published: 2020
Journal Articles

Cladribine, Idarubicin, Cytarabine (ara-C), and Venetoclax in Treating Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Patrick K Reville, MD, Hagop M. Kantarjian, MD, Gautam Borthakur, MD, Musa Yilmaz, MD, Guillermo Montalban-Bravo, MD, Courtney D. DiNardo, MD MSCE, Michael Andreeff, MD PhD, Naval Daver, MD, Nitin Jain, MD, Steven M. Kornblau, MD, Elias Jabbour, MD, Nicholas J. Short, MD, Yesid Alvarado, MD, Maro Ohanian, DO, Prithviraj Bose, MD, Lucia Masarova, MD, Sa A Wang, MD, Rebecca S. S Tidwell, MS, Zeev E. Estrov, MD, Guillermo Garcia-Manero, MD, Marina Konopleva, MD PhD, Farhad Ravandi, MBBS, Tapan M. Kadia, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 7–9.
https://doi.org/10.1182/blood-2020-141075
Published: 2020
Journal Articles

Outcomes of Chronic Myelomonocytic Leukemia (CMML) after Hypomethylating Agent (HMA) Failure

Veronia Guerra, Jorge M. Ramos Perez, MD, Danielle Hammond, MD, Kelly S. Chien, MD, Rashmi Kanagal-Shamanna, MD, Kiran Naqvi, MD MPH, Koji Sasaki, MD, Shilpa Paul, PharmD, Tapan M. Kadia, MD, Courtney D. DiNardo, MD MSCE, Marina Konopleva, MD PhD, Naval Daver, MD, Farhad Ravandi, MBBS, Naveen Pemmaraju, MD, Nicholas J. Short, MD, Ghayas C. Issa, MD, Koichi Takahashi, MD PhD, Zeev E. Estrov, MD, Sherry A. Pierce, BSN, BA, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Guillermo Montalban Bravo, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–23.
https://doi.org/10.1182/blood-2020-139901
Published: 2020
Journal Articles

Genomic and Transcriptomic Differences of Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) and Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS)

Guillermo Montalban Bravo, MD, Rashmi Kanagal-Shamanna, MD, Faezeh Darbaniyan, PhD, Irene Ganan-Gomez, PhD, Koji Sasaki, MD, Kiran Naqvi, MD MPH, Yue Wei, PhD, Hui Yang, MD PhD, Kelly A. Soltysiak, PhD, Kelly S. Chien, MD, Carlos E. Bueso-Ramos, MD PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–19.
https://doi.org/10.1182/blood-2020-139983
Published: 2020
Journal Articles

Long-Term Follow up of a Phase II Study of Guadecitabine (SGI-110) in Patients with Higher-Risk Myelodysplastic Syndrome (MDS)

Kiyomi Morita, MDPhD, Guillermo Montalban Bravo, MD, Koji Sasaki, MD, Kristy R. Bodden, Feng Wang, PhD, Prithviraj Bose, MD, Yesid Alvarado, MD, Naval Daver, MD, Gautam Borthakur, MD, Farhad Ravandi, MBBS, Koichi Takahashi, MD PhD, Elias Jabbour, MD, Courtney D. DiNardo, MD MSCE, Naveen Pemmaraju, MD, Tapan M. Kadia, MD, Maro Ohanian, DO, Sherry A. Pierce, BSN, BA, Mohammad Azab, MD MSc, MBA, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 21–22.
https://doi.org/10.1182/blood-2020-140614
Published: 2020
Journal Articles

Final Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agent Therapy

Kelly S. Chien, MD, Gautam Borthakur, MD, Kiran Naqvi, MD MPH, Naval Daver, MD, Guillermo Montalban Bravo, MD, Jorge E. Cortes, MD, Courtney D. DiNardo, MD MSCE, Elias Jabbour, MD, Yesid Alvarado, MD, Michael Andreeff, MD PhD, Prithviraj Bose, MD, Nitin Jain, MD, Kimberly Sheppard, BSN, RN, Cheri Klingner-Winton, Sherry A. Pierce, BSN, BA, Xiao Qin Dong, Kelly A. Soltysiak, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 23–24.
https://doi.org/10.1182/blood-2020-141100
Published: 2020
Journal Articles

Only Hotspot SF3B1 K700E Mutation Is an Independent Predictor of Overall Survival in Myelodysplastic Syndromes

Rashmi Kanagal-Shamanna, MD, Guillermo Montalban Bravo, MD, Koji Sasaki, MD, Carlos E. Bueso-Ramos, MD PhD, Elias Jabbour, MD, Yue Wei, PhD, Faezeh Darbaniyan, PhD, Mark Routbort, MD PhD, Sherry A. Pierce, BSN, BA, Kelly A. Soltysiak, PhD, Keyur Patel, MD PhD, L. Jeffrey Medeiros, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 24–25.
https://doi.org/10.1182/blood-2020-141446
Published: 2020
Journal Articles

Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia

Guillermo Montalban Bravo, MD, Rashmi Kanagal-Shamanna, MD, Veronia Guerra, Jorge M. Ramos Perez, MD, Danielle Hammond, MD, Shilpa Paul, PharmD, Kiran Naqvi, MD MPH, Koji Sasaki, MD, Elias Jabbour, MD, Courtney D. DiNardo, MD MSCE, Koichi Takahashi, MD PhD, Marina Konopleva, MD PhD, Naveen Pemmaraju, MD, Tapan M. Kadia, MD, Farhad Ravandi, MBBS, Naval Daver, MD, Gautam Borthakur, MD, Zeev E. Estrov, MD, Joseph D. Khoury, MD, Sanam Loghavi, MD, Sherry A. Pierce, BSN, BA, Carlos E. Bueso-Ramos, MD PhD, Keyur Patel, MD PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 26–29.
https://doi.org/10.1182/blood-2020-137212
Published: 2020